Gagnon Advisors’s MaxCyte MXCT Stock Holding History

Gagnon Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-934,196	Closed	-$2.55M	–	27
2025 Q1	$2.55M	Buy	+934,196	New	+$3.68M	1.8%	23

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gagnon Advisors's MXCT Position: Q2 2025 in Review

Gagnon Advisors sold out of MaxCyte (MXCT) in Q2 2025, closing a stake of 934,196 shares — an estimated $2.55M sold.

Gagnon Advisors first reported a position in MXCT in Q1 2025 and held it in 1 quarter. The position peaked at $2.55M in Q1 2025. 120 funds tracked by Wall St. Rank hold MXCT as of Q2 2025.

Gagnon Advisors reported no remaining MaxCyte position as of Q2 2025 after selling out during the quarter.
Gagnon Advisors sold 934,196 MaxCyte shares in Q2 2025, an estimated $2.55M.
Gagnon Advisors first reported a position in MaxCyte in Q1 2025 and held it in 1 quarter.
Gagnon Advisors's MaxCyte position peaked at $2.55M in Q1 2025.
120 funds tracked by Wall St. Rank held MaxCyte as of Q2 2025.

Based on Gagnon Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.